Document Detail


Thrombolysis in acute myocardial infarction.
MedLine Citation:
PMID:  1591557     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reperfusion of ischaemic myocardium with thrombolytic agents during the early stages of acute myocardial infarction reduces the mortality rate and can limit infarct size with associated sparing of left ventricular function. Effective and safe regimens are now available and in the absence of contraindications thrombolysis should now form part of the standard management acute myocardial infarction.
Authors:
S R Holmberg
Related Documents :
21430127 - A novel lead configuration for optimal spatio-temporal detection of intracardiac repola...
7612317 - Assessment of the practicality and safety of thrombolysis with anistreplase given by ge...
7921367 - The role of thrombolytic therapy for acute myocardial infarction.
9594337 - Effects of patency of infarct-related coronary artery on acute outcome in acute myocard...
16630087 - Fragmented left sided qrs in absence of bundle branch block: sign of left ventricular a...
9870197 - Evaluation of a novel bioprosthetic heart valve incorporating anticalcification and ant...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of hospital medicine     Volume:  47     ISSN:  0007-1064     ISO Abbreviation:  Br J Hosp Med     Publication Date:    1992 Apr 15-May 5
Date Detail:
Created Date:  1992-06-30     Completed Date:  1992-06-30     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0171545     Medline TA:  Br J Hosp Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  572-6, 578-80     Citation Subset:  IM    
Affiliation:
Royal Sussex County Hospital, Brighton.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase / pharmacology,  therapeutic use
Clinical Protocols
Humans
Myocardial Infarction / drug therapy*,  etiology,  mortality,  physiopathology
Recombinant Proteins / pharmacology,  therapeutic use
Streptokinase / pharmacology,  therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / pharmacology,  therapeutic use
Urokinase-Type Plasminogen Activator / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 81669-57-0/Anistreplase; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hip replacement surgery.
Next Document:  New treatments in inflammatory bowel disease.